# Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease

> **NCT07448402** · — · NOT_YET_RECRUITING · sponsor: **Caja Costarricense de Seguro Social** · enrollment: 50 (estimated)

## Conditions studied

- Psoriasis
- Psoriasis Arthritis
- Psoriasis (PsO)

## Interventions

- **BIOLOGICAL:** Guselkumab (GUS)
- **BIOLOGICAL:** Risankizumab (RISA)

## Key facts

- **NCT ID:** NCT07448402
- **Lead sponsor:** Caja Costarricense de Seguro Social
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2031-05
- **Final completion:** 2031-05
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07448402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07448402, "Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07448402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*